Claims for Patent: 9,266,861

Summary for Patent: 9,266,861

Title:	Method of synthesizing thyroid hormone analogs and polymorphs thereof
Abstract:	The disclosure describes methods of synthesis of pyridazinone compounds as thyroid hormone analogs and their prodrugs. Preferred methods according to the disclosure allow for large-scale preparation of pyridazinone compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of pyridazinone compounds in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of a pyridazinone compound. Further disclosed is a method for treating resistance to thyroid hormone in a subject having at least one TRβ mutation.
Inventor(s):	II D. Keith Hester, Robert J. Duguid, Martha J. Kelly, Anna Chasnoff, Gang Dong, Edwin L. Crow, Duk Soon Choi, Lianhe Shu, Ping Wang
Assignee:	Hoffmann La Roche Inc, Madrigal Pharmaceuticals Inc
Application Number:	US14/660,720
Patent Claims:	1. A morphic form of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (“Compound A”) (Form I) characterized by an X-ray powder diffraction pattern including peaks at about 10.5, 18.7, 22.9, 23.6, and 24.7 degrees 2θ. 2. The morphic form of claim 1 characterized by an X-ray powder diffraction pattern further including peaks at about 8.2, 11.2, 15.7 16.4, 17.7, 30.0, and 32.2 degrees 2θ. 3. The morphic form of claim 1 characterized by an X-ray powder diffraction pattern substantially similar to that set forth in FIG. 1. 4. The morphic form of claim 1, wherein the morphic form has a purity of 95% or greater. 5. A pharmaceutical composition comprising a morphic form of claim 1 and a pharmaceutically acceptable carrier. 6. A synthetic process comprising: (a) contacting R1MgX or R1Li with a compound of Formula (I): to form a compound of Formula (II): in which R1 is isopropyl or isopropenyl, X is halo and R2 is H or an amine protecting group; and (b) converting the compound of Formula (II) to a compound of Formula (III): in the presence of a base when R1 is isopropenyl or in the presence of an oxidizing agent when R1 is isopropyl. 7. The process of claim 6, further comprising: (c), when present, removing the amine protecting group R2 of the compound of Formula (III) to form 6-(4-amino-2,6-dichlorophenoxy)-4-isopropylpyridazin-3(2H)-one. 8. The process of claim 6, wherein step (a) is performed by contacting R1MgX with the compound of Formula (I), in which R1 is isopropenyl and X is Br; or step (a) is performed by contacting R1MgX with the compound of Formula (I), in which R1 is isopropyl and X is Cl. 9. The process of claim 6, wherein the oxidizing agent in step (b) is bromine and step (b) is performed in the presence of an acid. 10. The process of claim 6, wherein R2 is acetyl or benzoyl. 11. The process of claim 7, further comprising: (d) converting 6-(4-amino-2,6-dichlorophenoxy)-4-isopropylpyridazin-3(2H)-one to 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (“Compound A”) by contacting 6-(4-amino-2,6-dichlorophenoxy)-4-isopropylpyridazin-3(2H)-one with ethyl (2-cyanoacetyl)carbamate and a metal nitrite followed by treatment with potassium acetate in DMAC. 12. A process of preparing the preparing the morphic form of claim 1, the process comprising: heating a mixture comprising a solvent and Compound A at a first temperature, and cooling the mixture to a second temperature that is lower than the first temperature so as to obtain the morphic form of claim 1, wherein the solvent is selected from ethanol, isopropanol, methyl isobutyl ketone and a combination thereof. 13. The process of claim 12, wherein the first temperature is between about 60° C. and about 80° C. 14. The process of claim 12, wherein the second temperature is between about 0° C. and about 60° C. 15. The process of claim 12, wherein the solvent is ethanol or methyl isobutyl ketone. 16. A process of preparing a morphic form of claim 1, the process comprising: heating a mixture comprising a solvent and Compound A at a first temperature, wherein the solvent is selected from ethanol, isopropanol, methyl isobutyl ketone and a combination thereof; cooling the mixture to a second temperature that is lower than the first temperature; filtering the mixture to obtain a filter cake; rinsing the filter cake with an organic solvent to obtain a rinsed filter cake; and drying the rinsed filter cake to obtain the morphic form of claim 1. 17. A process of preparing a morphic form of claim 1, the process comprising: heating a mixture comprising ethanol and Compound A at a first temperature; cooling the mixture to a second temperature that is lower than the first temperature but greater than about 40° C.; filtering the mixture at a temperature not lower than about 40° C. to obtain a filter cake; rinsing the filter cake at a temperature not lower than about 40° C. with ethanol to obtain a rinsed filter cake; and drying the rinsed filter cake at a temperature not lower than about 40° C. to obtain the morphic form of claim 1.